Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
暂无分享,去创建一个
S. Culine | B. Iacopetta | C. Theillet | M. Cuny | A. Kramar | H. Fontaine | J. Grenier | F. Courjal | V. Johannsdottir | Vala Johannsdottir
[1] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[2] J. Peyrat,et al. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] P. Meltzer,et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Jian Kuang,et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.
[5] S. Bautista,et al. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei , 1998, Genes, chromosomes & cancer.
[6] J W Gray,et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] Charles Theillet,et al. Full speed ahead for tumor screening , 1998, Nature Medicine.
[8] B. Iacopetta,et al. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[10] F. Révillion,et al. ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.
[11] J. Foekens,et al. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. , 1998, British Journal of Cancer.
[12] M. Inganäs,et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. , 1998, Cancer research.
[13] B. Iacopetta,et al. Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer , 1997, International journal of cancer.
[14] Z. Shao,et al. p21/waf1/cip1 and mdm‐2 expression in breast carcinoma patients as related to prognosis , 1997, International journal of cancer.
[15] R. Zeillinger,et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.
[16] D. Horsfall,et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer , 1997, Oncogene.
[17] J. Piette,et al. Mdm2: keeping p53 under control , 1997, Oncogene.
[18] J. Eyfjörd,et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. , 1996, British Journal of Cancer.
[19] D. Horsfall,et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.
[20] D. Schaid,et al. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Gray,et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] L. Holmberg,et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.
[23] E. Hovig,et al. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.
[24] I. Bièche,et al. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[25] K. Heimdal,et al. Prognostic significance of TP53 alterations in breast carcinoma. , 1993, British Journal of Cancer.
[26] E. Schuuring,et al. Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1 , 1993, Genes, chromosomes & cancer.
[27] J. Henry,et al. int‐2 Amplification in breast cancer: Association with decreased survival and relationship to amplification of c‐erbb‐2 and c‐myc , 1993, International journal of cancer.
[28] M. J. van de Vijver,et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. , 1992, Cancer research.
[29] P. Nowell. Mechanisms of tumor progression. , 1986, Cancer research.
[30] P. McCullagh,et al. Some aspects of analysis of covariance. , 1982, Biometrics.
[31] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[32] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[33] Thierry Soussi,et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects , 1997, Nucleic Acids Res..
[34] D. Schaid,et al. Erratum: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value (Proceedings of the National Academy of Science of the USA (February 6, 1996) 93 (1093-1096)) , 1996 .